FIG 2.
Relationship between the anti-PA IgG concentration and the dose of AVP-21D9 in humans. Anti-PA IgG concentration was measured by an MSD ECL assay. All subjects dosed with AVP-21D9 had measurable anti-PA IgG concentrations from 5 min postdose to day 28. After day 28, some values in some of the dose groups were below the LLOQ. The mean values for the AUC from 0 h to infinity (AUC0-∞) increased in a dose-proportional manner after i.v. infusion of single 0.3-, 1-, 3-, and 10-mg/kg doses of AVP-21D9. The mean t1/2 ranged from 20 to 27 days.